277 related articles for article (PubMed ID: 33046835)
21. Recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history.
Kang PC; Phuah SY; Sivanandan K; Kang IN; Thirthagiri E; Liu JJ; Hassan N; Yoon SY; Thong MK; Hui M; Hartman M; Yip CH; Mohd Taib NA; Teo SH
Breast Cancer Res Treat; 2014 Apr; 144(3):635-42. PubMed ID: 24578176
[TBL] [Abstract][Full Text] [Related]
22. BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
Eoh KJ; Park JS; Park HS; Lee ST; Han J; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ
Gynecol Oncol; 2017 Apr; 145(1):137-141. PubMed ID: 28159408
[TBL] [Abstract][Full Text] [Related]
23. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
24. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.
Sharma P; Klemp JR; Kimler BF; Mahnken JD; Geier LJ; Khan QJ; Elia M; Connor CS; McGinness MK; Mammen JM; Wagner JL; Ward C; Ranallo L; Knight CJ; Stecklein SR; Jensen RA; Fabian CJ; Godwin AK
Breast Cancer Res Treat; 2014 Jun; 145(3):707-14. PubMed ID: 24807107
[TBL] [Abstract][Full Text] [Related]
25. Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC).
El Ansari FZ; Jouali F; Marchoudi N; Bennani MM; Ghailani NN; Barakat A; Fekkak J
BMC Cancer; 2020 Aug; 20(1):747. PubMed ID: 32778078
[TBL] [Abstract][Full Text] [Related]
26. Analysis of BRCA1/2 variants of unknown significance in the prospective Korean Hereditary Breast Cancer study.
Kim JH; Park S; Park HS; Park JS; Lee ST; Kim SW; Lee JW; Lee MH; Park SK; Noh WC; Choi DH; Han W; Jung SH
Sci Rep; 2021 Apr; 11(1):8485. PubMed ID: 33875706
[TBL] [Abstract][Full Text] [Related]
27. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.
Spurdle AB; Couch FJ; Parsons MT; McGuffog L; Barrowdale D; Bolla MK; Wang Q; Healey S; Schmutzler R; Wappenschmidt B; Rhiem K; Hahnen E; Engel C; Meindl A; Ditsch N; Arnold N; Plendl H; Niederacher D; Sutter C; Wang-Gohrke S; Steinemann D; Preisler-Adams S; Kast K; Varon-Mateeva R; Ellis S; Frost D; Platte R; Perkins J; Evans DG; Izatt L; Eeles R; Adlard J; Davidson R; Cole T; Scuvera G; Manoukian S; Bonanni B; Mariette F; Fortuzzi S; Viel A; Pasini B; Papi L; Varesco L; Balleine R; Nathanson KL; Domchek SM; Offitt K; Jakubowska A; Lindor N; Thomassen M; Jensen UB; Rantala J; Borg Å; Andrulis IL; Miron A; Hansen TV; Caldes T; Neuhausen SL; Toland AE; Nevanlinna H; Montagna M; Garber J; Godwin AK; Osorio A; Factor RE; Terry MB; Rebbeck TR; Karlan BY; Southey M; Rashid MU; Tung N; Pharoah PD; Blows FM; Dunning AM; Provenzano E; Hall P; Czene K; Schmidt MK; Broeks A; Cornelissen S; Verhoef S; Fasching PA; Beckmann MW; Ekici AB; Slamon DJ; Bojesen SE; Nordestgaard BG; Nielsen SF; Flyger H; Chang-Claude J; Flesch-Janys D; Rudolph A; Seibold P; Aittomäki K; Muranen TA; Heikkilä P; Blomqvist C; Figueroa J; Chanock SJ; Brinton L; Lissowska J; Olson JE; Pankratz VS; John EM; Whittemore AS; West DW; Hamann U; Torres D; Ulmer HU; Rüdiger T; Devilee P; Tollenaar RA; Seynaeve C; Van Asperen CJ; Eccles DM; Tapper WJ; Durcan L; Jones L; Peto J; dos-Santos-Silva I; Fletcher O; Johnson N; Dwek M; Swann R; Bane AL; Glendon G; Mulligan AM; Giles GG; Milne RL; Baglietto L; McLean C; Carpenter J; Clarke C; Scott R; Brauch H; Brüning T; Ko YD; Cox A; Cross SS; Reed MW; Lubinski J; Jaworska-Bieniek K; Durda K; Gronwald J; Dörk T; Bogdanova N; Park-Simon TW; Hillemanns P; Haiman CA; Henderson BE; Schumacher F; Le Marchand L; Burwinkel B; Marme F; Surovy H; Yang R; Anton-Culver H; Ziogas A; Hooning MJ; Collée JM; Martens JW; Tilanus-Linthorst MM; Brenner H; Dieffenbach AK; Arndt V; Stegmaier C; Winqvist R; Pylkäs K; Jukkola-Vuorinen A; Grip M; Lindblom A; Margolin S; Joseph V; Robson M; Rau-Murthy R; González-Neira A; Arias JI; Zamora P; Benítez J; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Peterlongo P; Zaffaroni D; Barile M; Capra F; Radice P; Teo SH; Easton DF; Antoniou AC; Chenevix-Trench G; Goldgar DE; ; ; ; ;
Breast Cancer Res; 2014 Dec; 16(6):3419. PubMed ID: 25857409
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.
Gomes R; Spinola PDS; Brant AC; Matta BP; Nascimento CM; de Aquino Paes SM; Bonvicino CR; Dos Santos ACE; Moreira MAM
Breast Cancer Res Treat; 2021 Feb; 185(3):851-861. PubMed ID: 33128190
[TBL] [Abstract][Full Text] [Related]
29. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
[TBL] [Abstract][Full Text] [Related]
30. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
[TBL] [Abstract][Full Text] [Related]
31. Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
Zhang Y; Wu H; Yu Z; Li L; Zhang J; Liang X; Huang Q
BMC Cancer; 2022 Aug; 22(1):842. PubMed ID: 35918668
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
Engel C; Rhiem K; Hahnen E; Loibl S; Weber KE; Seiler S; Zachariae S; Hauke J; Wappenschmidt B; Waha A; Blümcke B; Kiechle M; Meindl A; Niederacher D; Bartram CR; Speiser D; Schlegelberger B; Arnold N; Wieacker P; Leinert E; Gehrig A; Briest S; Kast K; Riess O; Emons G; Weber BHF; Engel J; Schmutzler RK;
BMC Cancer; 2018 Mar; 18(1):265. PubMed ID: 29514593
[TBL] [Abstract][Full Text] [Related]
33. Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
Singer CF; Tan YY; Muhr D; Rappaport C; Gschwantler-Kaulich D; Grimm C; Polterauer S; Pfeiler G; Berger A; Tea MM
Cancer Med; 2019 Apr; 8(4):1875-1881. PubMed ID: 30821131
[TBL] [Abstract][Full Text] [Related]
34. Re: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.
Brown DL; Cole BF; Arrick BA
J Natl Cancer Inst; 1999 Jan; 91(1):90-1. PubMed ID: 9890178
[No Abstract] [Full Text] [Related]
35. Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients.
Kim YC; Zhao L; Zhang H; Huang Y; Cui J; Xiao F; Downs B; Wang SM
Oncotarget; 2016 Feb; 7(8):9600-12. PubMed ID: 26848529
[TBL] [Abstract][Full Text] [Related]
36. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
Zayas-Villanueva OA; Campos-Acevedo LD; Lugo-Trampe JJ; Hernández-Barajas D; González-Guerrero JF; Noriega-Iriondo MF; Ramírez-Sánchez IA; Martínez-de-Villarreal LE
BMC Cancer; 2019 Jul; 19(1):722. PubMed ID: 31331294
[TBL] [Abstract][Full Text] [Related]
37. Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan.
Rashid MU; Muhammad N; Amin A; Loya A; Hamann U
Breast Cancer Res Treat; 2017 Jan; 161(2):191-201. PubMed ID: 27826754
[TBL] [Abstract][Full Text] [Related]
38. Incidence of contralateral and ipsilateral breast cancers and prognosis in BRCA1/2 pathogenic variant carriers based on the Japanese HBOC Consortium registration.
Yoshimura A; Yokoyama S; Iwata H; Takaiso N; Nomizu T; Arai M; Nakamura S
J Hum Genet; 2021 Apr; 66(4):379-387. PubMed ID: 33037391
[TBL] [Abstract][Full Text] [Related]
39. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil.
Cipriano NM; de Brito AM; de Oliveira ES; de Faria FC; Lemos S; Rodrigues AN; de Oliveira Lopes D; Dos Santos LL
Breast Cancer; 2019 May; 26(3):397-405. PubMed ID: 30535581
[TBL] [Abstract][Full Text] [Related]
40. A multi-institutional study on the association between BRCA1/BRCA2 mutational status and triple-negative breast cancer in familial breast cancer patients.
Seong MW; Kim KH; Chung IY; Kang E; Lee JW; Park SK; Lee MH; Lee JE; Noh DY; Son BH; Park HL; Cho SI; Park SS; ; Kim SW
Breast Cancer Res Treat; 2014 Jul; 146(1):63-9. PubMed ID: 24894343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
